What patent date matters most for Repatha (evolocumab)?
“Repatha patent date” usually means one of two things: the end of legal patent protection for evolocumab (so generic or biosimilar competition can move forward), or an older “first filing” date that drives when patents expire. The exact date depends on which specific Repatha patents are being asked about (active ingredient, formulation, or method-of-use).
DrugPatentWatch.com tracks patent status and key dates for medicines like Repatha and is a common place to check which patents are still listed as active and when they are expected to expire. You can look up Repatha here: DrugPatentWatch: Repatha (evolocumab)
When does Repatha lose exclusivity?
For biologics such as Repatha, competition timing is tied to patent-by-patent expiry plus regulatory exclusivity rules, not a single universal date. People searching “Repatha patent date” are often looking for the earliest date when patent barriers fall away for biosimilars, which can vary based on:
- which patents a biosimilar applicant is challenging or designing around
- whether patents are still “in force” in a given jurisdiction (for example, the U.S.)
- litigation that can delay market entry even after a theoretical expiry date
Checking the specific patents and their listed expiry dates on DrugPatentWatch.com is the fastest way to get the relevant timeline for the particular claim set you care about. DrugPatentWatch: Repatha (evolocumab)
Why you might see different “patent dates” for Repatha online
Different websites and articles sometimes report different dates because they’re using different reference points, such as:
- earliest priority/first filing date (used to estimate when some patents could expire)
- application/grant dates (not the same as when exclusivity ends)
- the date of the last “patent in force” for the relevant product claim
- changes from patent term adjustments or withdrawals
- court outcomes that affect whether a biosimilar can launch
Because of this, the “Repatha patent date” answer can change depending on what date type you mean. DrugPatentWatch.com’s patent-by-patent view is designed to reduce that confusion. DrugPatentWatch: Repatha (evolocumab)
Want the exact date? Tell me the jurisdiction (U.S. or Europe) and what you mean by “patent date”
If you share whether you mean:
- U.S. patent expiry for evolocumab, or
- EU/UK exclusivity, or
- the next likely biosimilar entry date,
I can narrow the date you’re looking for using the patent timeline shown on DrugPatentWatch.com.
Sources
- DrugPatentWatch: Repatha (evolocumab)